Systematic review and meta-analysis of randomized controlled trials on the effects of obeticholic acid on the blood lipid profile: Insights into liver disorders and liver cancer

Mo1475 – Change in Lipids: Characteristics and Response to Obeticholic Acid (OCA) in Target-PBC, a Diverse, Large United States (US) Real-World Cohort

(2019) Cynthia Levy et al.   GASTROENTEROLOGY

FRI-037-Change in lipids: Characteristics and response to obeticholic acid in TARGET-PBC, a diverse, large United States real-world cohort

(2019) Cynthia Levy et al.   JOURNAL OF HEPATOLOGY

BMI modifies the effect of dietary fat on atherogenic lipids: a randomized clinical trial

(2019) Tine Mejlbo Sundfør et al.   AMERICAN JOURNAL OF CLINICAL NUTRITION

Obeticholic acid may increase the risk of gallstone formation in susceptible patients

(2019) Samer Al-Dury et al.   JOURNAL OF HEPATOLOGY

The trim-and-fill method for publication bias

(2019) Linyu Shi et al.   MEDICINE

Association Between Triglyceride Lowering and Reduction of Cardiovascular Risk Across Multiple Lipid-Lowering Therapeutic Classes: A Systematic Review and Meta-Regression Analysis of Randomized Controlled Trials

(2019) Nicholas A. Marston et al.   CIRCULATION

CONTROL: A randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients

(2019) Paul J. Pockros et al.   LIVER INTERNATIONAL

Impact of obeticholic acid on the lipoprotein profile in patients with non-alcoholic steatohepatitis

(2019) Mohammad Shadab Siddiqui et al.   JOURNAL OF HEPATOLOGY

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

(2019) Zobair M Younossi et al.   LANCET

Clinical and metabolic effects associated with weight changes and obeticholic acid in non-alcoholic steatohepatitis

(2018) B. Hameed et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

SR-B1: A Unique Multifunctional Receptor for Cholesterol Influx and Efflux

(2018) Wen-Jun Shen et al.   Annual Review of Physiology

Obeticholic acid raises LDL-cholesterol and reduces HDL-cholesterol in the Diet-Induced NASH (DIN) hamster model

(2018) François Briand et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

FXR activation by obeticholic acid or nonsteroidal agonists induces a human-like lipoprotein cholesterol change in mice with humanized chimeric liver

(2018) Romeo Papazyan et al.   JOURNAL OF LIPID RESEARCH

Men and women respond differently to rapid weight loss: Metabolic outcomes of a multi-centre intervention study after a low-energy diet in 2500 overweight, individuals with pre-diabetes (PREVIEW)

(2018) Pia Christensen et al.   DIABETES OBESITY & METABOLISM

Reverse Cholesterol Transport and Atherosclerosis

(2018) Anand Rohatgi   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

New developments in the treatment of primary biliary cholangitis – role of obeticholic acid

(2017) Manan Jhaveri et al.   Therapeutics and Clinical Risk Management

Effects of obeticholic acid on lipoprotein metabolism in healthy volunteers

(2016) R. Pencek et al.   DIABETES OBESITY & METABOLISM

Regulation of lipid metabolism by obeticholic acid in hyperlipidemic hamsters

(2016) Bin Dong et al.   JOURNAL OF LIPID RESEARCH

A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis

(2016) Frederik Nevens et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy of Obeticholic Acid in Patients With Primary Biliary Cirrhosis and Inadequate Response to Ursodeoxycholic Acid

(2015) Gideon M. Hirschfield et al.   GASTROENTEROLOGY

Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial

(2015) Brent A Neuschwander-Tetri et al.   LANCET

Farnesoid X receptor: a master regulator of hepatic triglyceride and glucose homeostasis

(2014) Yang Jiao et al.   ACTA PHARMACOLOGICA SINICA

The response of patients with bile acid diarrhoea to the farnesoid X receptor agonist obeticholic acid

(2014) J. R. F. Walters et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Small Dense Low-Density Lipoprotein-Cholesterol Concentrations Predict Risk for Coronary Heart Disease

(2014) Ron C. Hoogeveen et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Dissociation of Intestinal and Hepatic Activities of FXR and LXR  Supports Metabolic Effects of Terminal Ileum Interposition in Rodents

(2013) A. Mencarelli et al.   DIABETES

Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease

(2013) Sunder Mudaliar et al.   GASTROENTEROLOGY

Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats

(2013) Len Verbeke et al.   HEPATOLOGY

Upregulation of scavenger receptor class B type I expression by activation of FXR in hepatocyte

(2010) Fan Chao et al.   ATHEROSCLEROSIS

Identification of Novel Pathways That Control Farnesoid X Receptor-mediated Hypocholesterolemia

(2009) Yanqiao Zhang et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats

(2009) Sabrina Cipriani et al.   JOURNAL OF LIPID RESEARCH

Role of Bile Acids and Bile Acid Receptors in Metabolic Regulation

(2009) Philippe Lefebvre et al.   PHYSIOLOGICAL REVIEWS